摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[3-[4-(2-Methylimidazol-1-ylmethyl)phenylthio]phenyl]-3,4,5,6-tetrahydro-2H-pyran-4-carboxamide

中文名称
——
中文别名
——
英文名称
4-[3-[4-(2-Methylimidazol-1-ylmethyl)phenylthio]phenyl]-3,4,5,6-tetrahydro-2H-pyran-4-carboxamide
英文别名
4-{3-[4-(2-Methyl-imidazol-1-ylmethyl)-phenylsulfanyl]-phenyl}-tetrahydro-pyran-4-carboxylic acid amide;4-[3-[4-[(2-methylimidazol-1-yl)methyl]phenyl]sulfanylphenyl]oxane-4-carboxamide
4-[3-[4-(2-Methylimidazol-1-ylmethyl)phenylthio]phenyl]-3,4,5,6-tetrahydro-2H-pyran-4-carboxamide化学式
CAS
——
化学式
C23H25N3O2S
mdl
——
分子量
407.536
InChiKey
KCJNIMWWROPSRO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    29
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    95.4
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • 5-lipoxygenase inhibitors
    申请人:Pfizer Inc.
    公开号:US05883106A1
    公开(公告)日:1999-03-16
    Novel compounds having the ability to inhibit 5-lipoxygenase enzyme and having the following formula I: ##STR1## and the pharmaceutically acceptable salts thereof, wherein Ar.sup.1 is a heterocyclic moiety which is selected from imidazolyl, pyrrolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, indolyl, indazolyl and benzimidazolyl, which is bonded to X.sup.1 through a ring nitrogen atom, and which may be optionally substituted with one or two substituents selected from halo, hydroxy, cyano, amino, and C.sub.1-4 alkyl; X.sup.1 is a direct bond or C.sub.1-4 alkylene; Ar.sup.2 is phenylene optionally substituted with halo, hydroxy, cyano, and amino X.sup.2 is --A--X-- or --X--A-- wherein A is a direct bond or C.sub.1-4 alkylene and X is oxy, thio, sulfinyl or sulfonyl; Ar.sup.3 is phenylene, pyridylene, thienylene, furylene, oxazolylene or thiazolylene optionally substituted with one or two substituents selected from halo, hydroxy, cyano, amino and C.sub.1-4 alkyl; R.sup.1 and R.sup.2 are each C.sub.1-4 alkyl, or together they form a group of formula --D.sup.1 --Z--D.sup.2 -- which together with the carbon atom to which it is attached defines a ring having 3 to 8 atoms, wherein D.sup.1 and D.sup.2 are C.sub.1-4 alkylene and Z is a direct bond or oxy, thio, sulfinyl, sulfonyl, or vinylene, and D.sup.1 and D.sup.2 may be substituted by C.sub.1-3 alkyl; and Y is CONR.sup.3 R.sup.4, CN, C(R.sup.3).dbd.N--OR.sup.4, COOR.sup.3, COR.sup.3 or CSNR.sup.3 R.sup.4, wherein R.sup.3 and R.sup.4 are each H or C.sub.1-4 alkyl. These compounds are useful in the treatment or alleviation of inflammatory diseases, allergy and cardiovascular diseases in mammals and as the active ingredient in pharmaceutical compositions for treating such conditions.
    具有抑制5-脂氧合酶酶活性的新型化合物及其具有以下化学式I的药学可接受盐,其中Ar.sup.1是从咪唑基,吡咯基,吡唑基,1,2,3-三唑基,1,2,4-三唑基,吲哚基,吲哚咪唑基和苯并咪唑基中选取的杂环基,通过一个环氮原子与X.sup.1连接,并且可以选择性地被卤素,羟基,氰基,氨基和C.sub.1-4烷基中的一个或两个取代基取代;X.sup.1是直接键或C.sub.1-4烷基;Ar.sup.2是苯基,可以选择性地被卤素,羟基,氰基和氨基取代;X.sup.2是--A--X--或--X--A--,其中A是直接键或C.sub.1-4烷基,X是氧,硫,亚硫酰基或磺酰基;Ar.sup.3是苯基,吡啶基,噻吩基,呋喃基,噁唑基或噻唑基,可以选择性地被一个或两个卤素,羟基,氰基,氨基和C.sub.1-4烷基取代;R.sup.1和R.sup.2分别是C.sub.1-4烷基,或者它们一起形成一个具有3到8个原子的环的结构,其中D.sup.1和D.sup.2是C.sub.1-4烷基,Z是直接键或氧,硫,亚硫酰基,磺酰基或乙烯基,D.sup.1和D.sup.2可以被C.sub.1-3烷基取代;Y是CONR.sup.3 R.sup.4,CN,C(R.sup.3).dbd.N--OR.sup.4,COOR.sup.3,COR.sup.3或CSNR.sup.3 R.sup.4,其中R.sup.3和R.sup.4分别是H或C.sub.1-4烷基。这些化合物可用于治疗哺乳动物的炎症性疾病、过敏和心血管疾病,并作为治疗这些疾病的药物组合物的活性成分。
  • 5-LIPOXYGENASE INHIBITORS
    申请人:PFIZER INC.
    公开号:EP0787127B1
    公开(公告)日:2001-01-03
  • US6063928A
    申请人:——
    公开号:US6063928A
    公开(公告)日:2000-05-16
  • 5-Lipoxygenase inhibitors: convenient synthesis of 4-[3-(4-heterocyclylphenylthio)phenyl]-3,4,5,6-tetrahydro-2H-pyran-4-carboxamide analogues
    作者:Takashi Mano、Rodney W. Stevens、Yoshiyuki Okumura、Makoto Kawai、Takako Okumura、Minoru Sakakibara
    DOI:10.1016/j.bmcl.2005.03.041
    日期:2005.5
    A convenient synthetic route to 4-[3-(4-heterocyclylphenylthio)phenyl]-3,4,5,6-tetrahydro-2H-pyran-4-earboxamide analogues as 5-LO inhibitors is described. This methodology enabled rapid development of structure-activity relationships (SARs) leading to improvement of pharmacological properties. Thus, new compounds with higher 5-LO inhibitory potency were discovered. The stereo-chemistry requirements of the tetrahydropyran ring are also discussed. (c) 2005 Elsevier Ltd. All rights reserved.
查看更多